Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,082 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Breitenbuecher F, von Pawel J, Sebastian M, Kortsik C, Ting S, Kasper S, Wohlschläger J, Worm K, Morresi-Hauf A, Schad A, Westerwick D, Wehler B, Werner M, Munzert G, Gaschler-Markefski B, Schmid KW, Schuler M. Breitenbuecher F, et al. Among authors: schuler m. Oncol Res Treat. 2017;40(7-8):435-439. doi: 10.1159/000475503. Epub 2017 Jun 20. Oncol Res Treat. 2017. PMID: 28628916 Clinical Trial.
Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG. Schmidt M, et al. Among authors: schuler m. Breast Cancer Res Treat. 2011 Feb;125(3):637-46. doi: 10.1007/s10549-010-0856-5. Epub 2010 Mar 30. Breast Cancer Res Treat. 2011. PMID: 20352488
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J. Sebastian M, et al. Among authors: schuler m. J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4. J Thorac Oncol. 2010. PMID: 20526206 Free article. Clinical Trial.
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Köhler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbücher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-Incio D, Linden G, Skottky S, Lütkes P, Dechêne A, Paul A, Markus P, Schmid KW, Schuler M. Wiesweg M, et al. Among authors: schuler m. Eur J Cancer. 2013 Oct;49(15):3076-82. doi: 10.1016/j.ejca.2013.06.014. Epub 2013 Jul 19. Eur J Cancer. 2013. PMID: 23876834
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S. Welt A, et al. Among authors: schuler m. Breast Cancer Res Treat. 2013 Nov;142(1):81-8. doi: 10.1007/s10549-013-2718-4. Breast Cancer Res Treat. 2013. PMID: 24122392
1,082 results